US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Septerna, Inc.

22.28

-0.9850-4.23%

Volume:245.53K

Turnover:5.47M

Market Cap:997.57M

PE:-15.63

High:23.15

Open:22.68

Low:21.85

Close:23.27

52wk High:28.99

52wk Low:4.17

Shares:44.77M

Float Shares:18.20M

Volume Ratio:0.79

T/O Rate:1.35%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.4257

EPS(LYR):-7.2588

ROE:-22.38%

ROA:-14.32%

PB:2.57

PE(LYR):-3.07

Loading ...

Overview Company News Filings

Septerna to Participate in Upcoming Investor Conferences

Septerna’s SEP-631 Study: A Potential Game-Changer in Pharmaceutical Research

A Look at Septerna’s (SEPN) Valuation Following Board Appointment of Veteran R&D Leader

Simply Wall St.

We're Not Worried About Septerna's (NASDAQ:SEPN) Cash Burn

Simply Wall St.

BRIEF-Septerna Appoints Keith Gottesdiener, M.D., To Its Board Of Directors

Septerna, Inc. Expands Board with New R&D Chair

Septerna Inc. Files Initial Statement of Beneficial Ownership for Director Keith Michael Gottesdiener

Septerna Inc. Appoints Biotechnology Veteran Keith Gottesdiener, M.D., to Board of Directors as Chair of Newly Formed R&D Committee

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.d., to Its Board of Directors

THOMSON REUTERS

Press Release: Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Septerna Price Target Maintained With a $25.00/Share by Cantor Fitzgerald

Septerna to Participate in Upcoming Investor Conferences

Septerna Price Target Maintained With a $26.00/Share by HC Wainwright & Co.

Septerna Inc. Initiates Phase 1 Clinical Trial of SEP-631 for Mast Cell-Driven Diseases

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule Mrgprx2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

THOMSON REUTERS

Septerna Q2 EPS $(0.56) Misses $(0.34) Estimate, Sales $119.000K Miss $6.800M Estimate

Septerna Inc. Reports Q2 2025 Results: Net Loss Widens to $24.8 Million, Up from $16.4 Million in Q2 2024

Septerna Inc: Updated Cash Runway Expected to Support Operating Plans at Least Into 2029

THOMSON REUTERS

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Septerna Inc. Appoints Liz Bhatt as President While She Continues as COO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SEPN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SEPN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SEPN\",,,,,undefined,":{"symbol":"SEPN","market":"US","secType":"STK","nameCN":"Septerna, Inc.","latestPrice":22.28,"timestamp":1763404438635,"preClose":23.265,"halted":0,"volume":245525,"delay":0,"floatShares":18202732,"shares":44774192,"eps":-1.425664,"marketStatus":"Trading","change":-0.985,"latestTime":"11-17 13:34:02 EST","open":22.68,"high":23.15,"low":21.85,"amount":5465559.3496,"amplitude":0.055878,"askPrice":22.32,"askSize":102,"bidPrice":22.24,"bidSize":110,"shortable":3,"etf":0,"ttmEps":-1.425664,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1763413200000},"marketStatusCode":2,"adr":0,"listingDate":1729828800000,"exchange":"NASDAQ","adjPreClose":23.265,"preHourTrading":{"tag":"盘前","latestPrice":22.57,"preClose":23.265,"latestTime":"09:13 EST","volume":3109,"amount":69902.124873,"timestamp":1763388806844},"postHourTrading":{"tag":"盘后","latestPrice":23.2333,"preClose":23.265,"latestTime":"19:48 EST","volume":9030,"amount":210088.9135,"timestamp":1763167680999},"volumeRatio":0.7878,"impliedVol":0.9276,"impliedVolPercentile":0.7668},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SEPN\",,,,,undefined,":{"symbol":"SEPN","floatShares":18202732,"roa":"-14.32%","roe":"-22.38%","lyrEps":-7.258829,"volumeRatio":0.7878,"shares":44774192,"dividePrice":0,"high":23.15,"amplitude":0.055878,"preClose":23.265,"low":21.85,"week52Low":4.17,"pbRate":"2.57","psRate":"45.25","week52High":28.99,"institutionHeld":0,"latestPrice":22.28,"committee":0.037736,"eps":-1.425664,"divideRate":0,"volume":245525,"delay":0,"ttmEps":-1.425664,"open":22.68,"prevYearClose":22.9,"prevWeekClose":23.265,"prevMonthClose":20.6,"prevQuarterClose":18.81,"fiveDayClose":18.1,"twentyDayClose":22.44,"sixtyDayClose":11.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SEPN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-10","symbol":"SEPN","fiscalQuarterEnding":"2025/09","expectedEps":0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.09},{"market":"US","date":"2025-08-11","symbol":"SEPN","fiscalQuarterEnding":"2025/06","expectedEps":-0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-0.56},{"market":"US","date":"2025-05-15","symbol":"SEPN","fiscalQuarterEnding":"2025/03","expectedEps":-0.38,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-03-27","symbol":"SEPN","fiscalQuarterEnding":"2024/12","expectedEps":-0.69,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.64}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SEPN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SEPN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":5,"updateTime":1750827600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SEPN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SEPN","date":"2025-11-14","current":-16.318712,"percent":0.323194,"low":-71.269737,"twenty":-35.886473,"median":-7.487327,"eighty":-5.196633,"high":261.261398,"avg":-2.425657,"sd":66.226261,"marketCap":861455454},"quantilePoints":[{"date":"2024-10-25","current":180.873276,"twenty":180.873276,"median":180.873276,"eighty":180.873276,"marketCap":756050292},{"date":"2024-10-31","current":204.688257,"twenty":197.111676,"median":204.688257,"eighty":209.813,"marketCap":855596913},{"date":"2024-11-08","current":261.261398,"twenty":203.984861,"median":216.997688,"eighty":242.57116,"marketCap":1092072644},{"date":"2024-11-15","current":224.885772,"twenty":207.743006,"median":230.613426,"eighty":256.156752,"marketCap":940022529},{"date":"2024-11-22","current":-56.371082,"twenty":203.984861,"median":228.503238,"eighty":245.706296,"marketCap":915240881},{"date":"2024-11-29","current":-69.163916,"twenty":-57.105794,"median":221.92146,"eighty":240.581553,"marketCap":1122945345},{"date":"2024-12-06","current":-68.890433,"twenty":-66.926823,"median":208.506693,"eighty":237.707678,"marketCap":1118505070},{"date":"2024-12-13","current":-61.725172,"twenty":-67.501138,"median":191.022276,"eighty":236.763117,"marketCap":1002169886},{"date":"2024-12-20","current":-63.995083,"twenty":-66.784612,"median":-58.207863,"eighty":234.592638,"marketCap":1039024162},{"date":"2024-12-27","current":-70.449288,"twenty":-68.420042,"median":-60.166317,"eighty":232.180994,"marketCap":1143814633},{"date":"2025-01-03","current":-58.388676,"twenty":-68.655237,"median":-61.232902,"eighty":229.769351,"marketCap":947998541},{"date":"2025-01-10","current":-57.02126,"twenty":-67.714455,"median":-60.412452,"eighty":226.39305,"marketCap":925797170},{"date":"2025-01-17","current":-46.437457,"twenty":-67.358927,"median":-58.853597,"eighty":224.885772,"marketCap":753958559},{"date":"2025-01-24","current":-50.266223,"twenty":-66.593173,"median":-57.614562,"eighty":220.142874,"marketCap":816122397},{"date":"2025-01-31","current":-48.433885,"twenty":-66.401735,"median":-55.982023,"eighty":215.822012,"marketCap":786372560},{"date":"2025-02-07","current":-38.861971,"twenty":-65.110894,"median":-50.840537,"eighty":209.813,"marketCap":630962963},{"date":"2025-02-14","current":-31.587316,"twenty":-64.153703,"median":-49.199638,"eighty":205.451944,"marketCap":512851670},{"date":"2025-02-21","current":-16.108164,"twenty":-63.748948,"median":-46.492154,"eighty":202.578068,"marketCap":261532150},{"date":"2025-02-28","current":-15.862029,"twenty":-63.55204,"median":-46.410109,"eighty":188.992476,"marketCap":257535903},{"date":"2025-03-07","current":-17.393535,"twenty":-63.169163,"median":-46.191322,"eighty":63.291545,"marketCap":282401439},{"date":"2025-03-14","current":-17.47558,"twenty":-62.928498,"median":-43.237703,"eighty":-15.145503,"marketCap":283733521},{"date":"2025-03-21","current":-16.81922,"twenty":-62.747999,"median":-39.764466,"eighty":-15.424456,"marketCap":273076863},{"date":"2025-03-28","current":-3.893469,"twenty":-62.08617,"median":-37.439858,"eighty":-15.424456,"marketCap":279543299},{"date":"2025-04-04","current":-3.590162,"twenty":-61.462628,"median":-35.44343,"eighty":-3.701581,"marketCap":257766476},{"date":"2025-04-11","current":-3.194007,"twenty":-61.271189,"median":-31.04035,"eighty":-3.397655,"marketCap":229323279},{"date":"2025-04-17","current":-3.707771,"twenty":-61.249311,"median":-18.610536,"eighty":-3.429843,"marketCap":266210551},{"date":"2025-04-25","current":-3.998698,"twenty":-60.904722,"median":-17.913153,"eighty":-3.49979,"marketCap":287098524},{"date":"2025-05-02","current":-4.419614,"twenty":-60.313998,"median":-17.530277,"eighty":-3.557975,"marketCap":317319421},{"date":"2025-05-09","current":-4.302005,"twenty":-59.827198,"median":-17.393535,"eighty":-3.586448,"marketCap":308875347},{"date":"2025-05-16","current":-5.700187,"twenty":-58.946582,"median":-17.1474,"eighty":-3.607494,"marketCap":450930380},{"date":"2025-05-23","current":-5.339701,"twenty":-58.316351,"median":-16.81922,"eighty":-3.64092,"marketCap":422413044},{"date":"2025-05-30","current":-5.553739,"twenty":-57.970542,"median":-16.682479,"eighty":-3.660728,"marketCap":439345212},{"date":"2025-06-06","current":-5.925491,"twenty":-56.891224,"median":-16.203883,"eighty":-3.697867,"marketCap":468753715},{"date":"2025-06-13","current":-5.863532,"twenty":-56.29327,"median":-16.053467,"eighty":-3.717675,"marketCap":463852298},{"date":"2025-06-20","current":-5.908593,"twenty":-55.982023,"median":-15.862029,"eighty":-3.757291,"marketCap":467416965},{"date":"2025-06-27","current":-6.122632,"twenty":-53.001056,"median":-15.383433,"eighty":-3.77586,"marketCap":484349134},{"date":"2025-07-03","current":-6.404261,"twenty":-51.513306,"median":-10.750269,"eighty":-3.795668,"marketCap":506628303},{"date":"2025-07-11","current":-6.578872,"twenty":-50.660039,"median":-6.404261,"eighty":-3.874899,"marketCap":520441387},{"date":"2025-07-18","current":-7.108336,"twenty":-50.32092,"median":-6.590137,"eighty":-3.893469,"marketCap":562326225},{"date":"2025-07-25","current":-7.6378,"twenty":-49.412955,"median":-6.753482,"eighty":-3.9727,"marketCap":604211063},{"date":"2025-08-01","current":-6.990051,"twenty":-48.587036,"median":-6.961888,"eighty":-3.99746,"marketCap":552968974},{"date":"2025-08-08","current":-6.590137,"twenty":-46.8805,"median":-6.764747,"eighty":-3.998698,"marketCap":521332554},{"date":"2025-08-15","current":-5.951139,"twenty":-46.492154,"median":-6.643647,"eighty":-4.11805,"marketCap":520754376},{"date":"2025-08-22","current":-5.961329,"twenty":-46.448396,"median":-6.601402,"eighty":-4.167728,"marketCap":521646079},{"date":"2025-08-29","current":-6.256848,"twenty":-46.3937,"median":-6.581688,"eighty":-4.266238,"marketCap":547505457},{"date":"2025-09-05","current":-7.194356,"twenty":-46.300716,"median":-6.581688,"eighty":-4.297053,"marketCap":629542106},{"date":"2025-09-12","current":-7.34721,"twenty":-46.213201,"median":-6.601402,"eighty":-4.305719,"marketCap":642917646},{"date":"2025-09-19","current":-8.121674,"twenty":-44.993466,"median":-6.643647,"eighty":-4.319893,"marketCap":710687051},{"date":"2025-09-26","current":-8.534381,"twenty":-43.94876,"median":-6.764747,"eighty":-4.33085,"marketCap":746801011},{"date":"2025-10-03","current":-10.266733,"twenty":-43.12831,"median":-6.961888,"eighty":-4.351524,"marketCap":898390470},{"date":"2025-10-10","current":-11.790184,"twenty":-42.592283,"median":-7.068908,"eighty":-4.39733,"marketCap":1031700023},{"date":"2025-10-17","current":-11.497212,"twenty":-40.869338,"median":-7.146788,"eighty":-4.427042,"marketCap":1006063571},{"date":"2025-10-24","current":-11.102338,"twenty":-39.518331,"median":-7.194356,"eighty":-4.55084,"marketCap":971510091},{"date":"2025-10-31","current":-10.949483,"twenty":-39.058879,"median":-7.339567,"eighty":-4.913908,"marketCap":958134551},{"date":"2025-11-07","current":-9.578887,"twenty":-37.155435,"median":-7.357401,"eighty":-5.147066,"marketCap":838200538},{"date":"2025-11-14","current":-14.648361,"twenty":-35.886473,"median":-7.487327,"eighty":-5.196633,"marketCap":861455454}],"updateTime":1763366292660},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SEPN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2580213168","title":"Septerna to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213168","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580213168?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:00","pubTimestamp":1762174800,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov.  03, 2025  (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug di","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179226/0/en/Septerna-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","SEPN","BK4007"],"gpt_icon":0},{"id":"2578627511","title":"Septerna’s SEP-631 Study: A Potential Game-Changer in Pharmaceutical Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2578627511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578627511?lang=en_us&edition=fundamental","pubTime":"2025-10-28 02:54","pubTimestamp":1761591291,"startTime":"0","endTime":"0","summary":"Septerna, Inc. (($SEPN)) announced an update on their ongoing clinical study. Septerna, Inc. (SEPN) is conducting a Phase 1 clinical study titled A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/septernas-sep-631-study-a-potential-game-changer-in-pharmaceutical-research?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/septernas-sep-631-study-a-potential-game-changer-in-pharmaceutical-research?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2574183898","title":"A Look at Septerna’s (SEPN) Valuation Following Board Appointment of Veteran R&D Leader","url":"https://stock-news.laohu8.com/highlight/detail?id=2574183898","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574183898?lang=en_us&edition=fundamental","pubTime":"2025-10-09 06:18","pubTimestamp":1759961881,"startTime":"0","endTime":"0","summary":"Septerna has announced that Keith Gottesdiener, M.D., will join its board of directors and chair a new R&D Committee. Dr. Gottesdiener’s extensive leadership in drug development adds an intriguing dynamic to Septerna’s long-term strategy and pipeline outlook.\nSee our latest analysis for Septerna.\nSepterna’s recent move to appoint Dr. Gottesdiener comes as momentum starts to build. The stock’s 7-day share price return sits at an impressive 11.7%, and its 30-day return has soared 45.6%, even as...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/a-look-at-septernas-sepn-valuation-following-board-appointme","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/a-look-at-septernas-sepn-valuation-following-board-appointme","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2573648313","title":"We're Not Worried About Septerna's (NASDAQ:SEPN) Cash Burn","url":"https://stock-news.laohu8.com/highlight/detail?id=2573648313","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573648313?lang=en_us&edition=fundamental","pubTime":"2025-10-05 20:31","pubTimestamp":1759667488,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/were-not-worried-about-septernas-nasdaqsepn-cash-burn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/were-not-worried-about-septernas-nasdaqsepn-cash-burn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MNQmain","QLD","TQQQ","TSYW.SI","NQmain","SEPN",".IXIC","USJW.SI","USAW.SI","QID","SQQQ","NVIW.SI","BK4007","PSQ"],"gpt_icon":1},{"id":"2571366632","title":"BRIEF-Septerna Appoints Keith Gottesdiener, M.D., To Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2571366632","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571366632?lang=en_us&edition=fundamental","pubTime":"2025-09-30 06:16","pubTimestamp":1759184184,"startTime":"0","endTime":"0","summary":"BRIEF-Septerna Appoints Keith Gottesdiener, M.D., To Its Board Of DirectorsSept 29 (Reuters) - Septerna Inc SEPN.O:SEPTERNA APPOINTS VETERAN BIOTECHNOLOGY LEADER KEITH GOTTESDIENER, M.D., TO ITS BOARD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUAMWMZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4007"],"gpt_icon":0},{"id":"2571635943","title":"Septerna, Inc. Expands Board with New R&D Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2571635943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571635943?lang=en_us&edition=fundamental","pubTime":"2025-09-30 05:00","pubTimestamp":1759179632,"startTime":"0","endTime":"0","summary":"An update from Septerna, Inc. ( ($SEPN) ) is now available. On September 25, 2025, Septerna, Inc. expanded its Board of Directors by appointing Kei...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/septerna-inc-expands-board-with-new-rd-chair?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/septerna-inc-expands-board-with-new-rd-chair?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2571368025","title":"Septerna Inc. Files Initial Statement of Beneficial Ownership for Director Keith Michael Gottesdiener","url":"https://stock-news.laohu8.com/highlight/detail?id=2571368025","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571368025?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:58","pubTimestamp":1759179514,"startTime":"0","endTime":"0","summary":"Septerna Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names Keith Michael Gottesdiener as a beneficial owner in his capacity as Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Septerna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL4DDSwS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2571357727","title":"Septerna Inc. Appoints Biotechnology Veteran Keith Gottesdiener, M.D., to Board of Directors as Chair of Newly Formed R&D Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2571357727","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571357727?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:01","pubTimestamp":1759176068,"startTime":"0","endTime":"0","summary":"Septerna Inc. Appoints Biotechnology Veteran Keith Gottesdiener, M.D., to Board of Directors as Chair of Newly Formed R&D Committee. Septerna Inc. has announced the appointment of Keith Gottesdiener, M.D., to its board of directors. Dr. Gottesdiener will serve as chairperson of a newly formed R&D Committee. He brings over 30 years of experience in biotechnology, including leadership roles at Prime Medicine, Rhythm Pharmaceuticals, and Merck Research Laboratories.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Septerna Inc. published the original content used to generate this news brief via GlobeNewswire  on September 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL1rnq6H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","LU0314104364.USD","IE00BKPKM429.USD","PRME","SEPN","NDAQ","BK4585","BK4007","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","RYTM","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139"],"gpt_icon":0},{"id":"2571242357","title":"Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.d., to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2571242357","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571242357?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:01","pubTimestamp":1759176060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUAMWMZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SEPN","BK4007"],"gpt_icon":0},{"id":"2571760357","title":"Press Release: Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2571760357","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571760357?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:01","pubTimestamp":1759176060,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025  -- Septerna, Inc. , a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor  drug discovery, today announced the appointment of Keith Gottesdiener, M.D., to its board of directors. A seasoned biotechnology executive with over 30 years of experience advancing medicines from discovery through commercialization, Dr. Gottesdiener will serve as chairperson of a newly constituted R&D Committee of the Board.\"Dr. Gottesdiener's exceptional track record of successfully advancing novel therapeutics from discovery through development to approval, combined with his deep expertise in regulatory strategy and clinical development across multiple therapeutic areas, will be invaluable as we advance our lead programs and build Septerna into a premier GPCR therapeutics company,\" said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. \"His appointment comes at a pivotal time as we advance our lead p","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4555","BK4588","BK4585","BK4604","BK4007","03160","BK4599","GPCR","BK4099","TM"],"gpt_icon":0},{"id":"2565106566","title":"Septerna Price Target Maintained With a $25.00/Share by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2565106566","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565106566?lang=en_us&edition=fundamental","pubTime":"2025-09-05 22:02","pubTimestamp":1757080920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SEPN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 05, 2025 10:02 ET (14:02 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN"],"gpt_icon":0},{"id":"2562465757","title":"Septerna to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2562465757","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562465757?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:00","pubTimestamp":1756296000,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Aug.  27, 2025  (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/27/3139942/0/en/Septerna-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2561990314","title":"Septerna Price Target Maintained With a $26.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2561990314","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561990314?lang=en_us&edition=fundamental","pubTime":"2025-08-21 22:48","pubTimestamp":1755787680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SEPN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 21, 2025 10:48 ET (14:48 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN"],"gpt_icon":0},{"id":"2561383467","title":"Septerna Inc. Initiates Phase 1 Clinical Trial of SEP-631 for Mast Cell-Driven Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2561383467","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561383467?lang=en_us&edition=fundamental","pubTime":"2025-08-21 20:00","pubTimestamp":1755777628,"startTime":"0","endTime":"0","summary":"Septerna Inc., a clinical-stage biotechnology company, has announced the initiation of a Phase 1 clinical trial for SEP-631, a selective oral small molecule MRGPRX2 negative allosteric modulator. The trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SEP-631 in healthy adult volunteers. This development targets the treatment of chronic spontaneous urticaria and other mast cell-driven diseases. The trial is designed as a randomized, placebo-controlled study and will involve up to approximately 150 participants. Currently, dosing is in progress in the single-ascending dose segment of the trial. Future results of the trial are anticipated but have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250821:nNDL2KQk0j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","LU0314104364.USD","SEPN","LU2095319765.USD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","BK4588"],"gpt_icon":0},{"id":"2561462035","title":"Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule Mrgprx2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2561462035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561462035?lang=en_us&edition=fundamental","pubTime":"2025-08-21 20:00","pubTimestamp":1755777603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250821:nTUA7NML4P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2558557698","title":"Septerna Q2 EPS $(0.56) Misses $(0.34) Estimate, Sales $119.000K Miss $6.800M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2558557698","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558557698?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:25","pubTimestamp":1754943909,"startTime":"0","endTime":"0","summary":"Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.34) by 66.17 percent.  The company reported quarterly sales of $119.000 thousand which missed the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47044385/septerna-q2-eps-0-56-misses-0-34-estimate-sales-119-000k-miss-6-800m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Septerna Q2 EPS $(0.56) Misses $(0.34) Estimate, Sales $119.000K Miss $6.800M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN"],"gpt_icon":0},{"id":"2558660503","title":"Septerna Inc. Reports Q2 2025 Results: Net Loss Widens to $24.8 Million, Up from $16.4 Million in Q2 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2558660503","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558660503?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:01","pubTimestamp":1754942480,"startTime":"0","endTime":"0","summary":"Septerna Inc. has reported its financial results for the second quarter of 2025. The company experienced a net loss of $24.8 million for the quarter ended June 30, 2025, compared to a net loss of $16.4 million in the same period the previous year. Research and development expenses rose to $22.2 million from $15.0 million year-over-year, reflecting an increase in R&D activities. General and administrative expenses also increased to $6.9 million from $3.4 million in the previous year. In terms of cash position, Septerna's cash, cash equivalents, and marketable securities stood at $379.2 million as of June 30, 2025. Following the receipt of a $195 million upfront payment from Novo Nordisk in July, the company now expects its cash runway to extend at least into 2029. Significant business updates include advancing the selection of a next-generation oral small molecule PTH1R agonist for clinical development and initiating a Phase 1 trial for SEP-631, MRGPRX2 NAM program, targeting mast cell ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDL4JV5Yb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU2210149790.SGD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ","LU0314104364.USD","SEPN","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","BK4007","BK4588"],"gpt_icon":0},{"id":"2558602096","title":"Septerna Inc: Updated Cash Runway Expected to Support Operating Plans at Least Into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2558602096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558602096?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:01","pubTimestamp":1754942460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nTUA1XVSNC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2558983466","title":"Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2558983466","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558983466?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:01","pubTimestamp":1754942460,"startTime":"0","endTime":"0","summary":"Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3131210/0/en/Septerna-Highlights-Business-Progress-and-Reports-Second-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","LU1992135399.USD","LU2065732104.USD","LU2272731782.SGD","SEPN","PRGS","COO","GPCR","BK4588","LU2211815571.USD","BK4585","BK4097","LU2272731600.USD","LU1992135472.HKD","GB00BDT5M118.USD","BK4198"],"gpt_icon":0},{"id":"2557339755","title":"Septerna Inc. Appoints Liz Bhatt as President While She Continues as COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2557339755","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557339755?lang=en_us&edition=fundamental","pubTime":"2025-08-05 04:06","pubTimestamp":1754337999,"startTime":"0","endTime":"0","summary":"Septerna Inc. has announced a management change effective August 1, 2025. Liz Bhatt, the company's Chief Operating Officer since June 2022, has been appointed as President. She will take over the role from Jeffrey Finer, who will continue to serve as Chief Executive Officer. There are no familial or transactional ties influencing Ms. Bhatt's appointment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Septerna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL1p93B3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":45,"code":"91000000","status":"200"}]}}